DIPG-61. RESCUE REGIMENS AFTER BIOMEDE: POSSIBLE INFLUENCE ON OS ASSESSMENT

BIOMEDE is a multicentric randomized phase II trial to evaluate in DIPG the OS of patients treated with dasatinib, erlotinib or everolimus. The OS is the result of the first line treatment but it could also be affected by re-irradiation and the second line treatment received after progression, espec...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Carlo, Daniela Di, Pommier, Bertille, Teuff, Gwenael Le, Abbou, Samuel, Berlanga, Pablo, Geoerger, Birgit, Puget, Stephanie, Beccaria, Kevin, Blauwblomme, Thomas, Debily, Marie-Anne, Castel, David, Lechapt, Emmanuelle, Varlet, Pascale, Dangouloff-Ros, Volodia, Boddaert, Nathalie, Vassal, Gilles, Deley, Marie-Cécile Le, Grill, Jacques
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Diffuse Midline Glioma/DIPG
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7715765/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa222.106
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados